CEO presents at the 2015 Stem Cell meeting on the MESA
Guildford, UK, 17 April 2015: Long term data continue to show good safety profile and evidence of sustained improvements in neurological status and limb function.
Guildford, UK, 7 May 2014: ReNeuron Group plc (the “Company”) (AIM: RENE.L) today provides a further update on the PISCES Phase I clinical trial of its ReN001 stem cell therapy for disabled stroke patients ahead of the commencement of a Phase II efficacy study for which patient enrolment has now opened.
Guildford, UK, 7 May 2014: ReNeuron Group plc (the “Company”) (AIM: RENE.L) today provides a further update on the PISCES Phase I clinical trial of its ReN001 stem cell therapy for disabled stroke patients ahead of the commencement of a Phase II efficacy study for which patient enrolment has now opened.
Guildford, UK, 14 June 2012: ReNeuron is pleased to announce the presentation of interim data from the PISCES (Pilot Investigation of Stem Cells in Stroke) clinical trial of its ReN001 stem cell therapy for disabled stroke patients.